Table of Contents
When Brazil’s health regulator ANVISA quietly approved a long-awaited framework for domestic cannabis cultivation in January, it did something few markets have attempted. It legalized a tightly controlled medical supply chain without prescribing the digital infrastructure that will keep it in check. Instead of mandating a single state-run tracking system, Brazil defined strict traceability outcomes and told operators to bring their own compliant technology, setting the stage for a new era of Brazil cannabis compliance.
Into that gap steps GrowerIQ, a Canadian cannabis compliance and operations platform now formalizing operations in Brazil through a strategic alliance with genetics company Milgrows. The move positions GrowerIQ as the first international seed to sale system to enter the country ahead of an August 4 regulatory deadline and underscores how quickly Brazil’s new rules are forcing patient associations and prospective cultivators to professionalize.
A different kind of Brazil cannabis compliance model
GrowerIQ is what the industry calls a seed to sale system. The software tracks every cannabis plant and product from planting through harvest, processing, laboratory testing, and final sale, creating a complete and auditable compliance record for regulators and auditors. The platform already powers facilities in more than 24 countries and seven languages, including Canada’s federal market, multiple United States state programs integrated with government traceability, and several emerging European and Latin American medical programs.
In most United States markets, regulators select a specific government approved traceability platform, often Metrc, and every license holder must plug into that system. Brazil has taken a different route. ANVISA has defined what compliant operations must achieve, including seed to product traceability, per batch laboratory testing, and georeferenced facility documentation, but leaves operators responsible for selecting and implementing systems that can prove it. For operators navigating Brazil cannabis compliance, that means technology choices are open, but documentation expectations are high.
According to GrowerIQ, that model tends to reward platforms with proven international track records rather than software built for a single jurisdiction. For Brazil, the company says the work was less about rebuilding the product and more about contextualizing it. That has meant understanding how Brazilian facilities are structured, how ANVISA documentation works in practice, and how georeferencing and lab integrations should behave in local conditions. GrowerIQ also frames its platform as infrastructure, an enterprise-style seed-to-sale and quality management system designed to generate audit-ready records by default.
Why Milgrows is central to the strategy
That localization work is where Milgrows comes in. Founded in 2019, the Brazilian agribusiness has built its reputation on cannabis genetics, curating more than 560 cultivars from six international seed banks and advising growers operating across Brazil’s diverse biomes. Its team has spent six years working with patient associations and cultivators who depend on reliable seeds and tailored genetics to support court-authorized treatments, often in challenging environments with very different climate and agronomic profiles.
GrowerIQ notes that compliance software alone cannot tell a Brazilian operator which of those 560 plus cultivars performs best in a given biome or how a small patient association that has never run a licensed facility should structure its grow. That is the gap Milgrows fills. Under the alliance, Milgrows contacts gain direct access to a compliance platform built to meet ANVISA’s traceability and documentation requirements. At the same time, GrowerIQ’s Brazilian clients gain a genetics and cultivation partner who understands local agronomy and patient realities.
In practical terms, that means an association entering the Regulatory Sandbox can plan its facility layout, choose appropriate genetics, and deploy compliant software in a coordinated way rather than trying to assemble separate solutions under intense time pressure.
Racing an August deadline in a market already in motion
Brazil’s medical cannabis market is not starting from zero. Recent market analyses estimate it was worth roughly 856 million US dollars in 2025 and could reach about 1.55 billion US dollars by 2034, driven by steady growth in prescriptions and products. More than 50,000 physicians have already prescribed cannabis based treatments, and hundreds of thousands of patients currently rely on imported products or magistral preparations.
What Brazil has lacked until now is a legal framework for domestic cultivation. On January 28, ANVISA approved a new regulatory package that, among other measures, establishes an experimental Regulatory Sandbox for medical cannabis cultivation by nonprofit patient associations and sets detailed cultivation and traceability requirements for medical and research purposes. The framework takes effect in August 2026, giving early participants a narrow window to design, implement, and validate fully compliant operations.
More than 300 patient associations are expected to seek authorization under the Sandbox, but most are grassroots organizations built around access and advocacy rather than pharmaceutical style production. GrowerIQ argues that these groups need genetics expertise and traceability infrastructure at the same time, not one after the other. The alliance with Milgrows is pitched as a way for them to access both from a single channel instead of sourcing and integrating two separate solutions under a six month compliance deadline.
In the near term, domestic cultivation’s most visible impact is likely to be on price and access. Local production has the potential to reduce the cost premium associated with imports and to calibrate supply more closely to Brazilian patient needs rather than international export markets. For companies focused on Brazil cannabis compliance, the immediate challenge is to implement systems where every batch is tested, every transfer documented, and every facility verifiable in ways that regulators and prescribing physicians can trust. GrowerIQ sees its role as providing that compliance backbone.
From proving compliance to building an intelligence layer
Internally, GrowerIQ describes a shift from proving compliance to using compliance data. In more mature markets, the company says its clients are mining traceability records to spot yield inefficiencies, optimize batch schedules, and reduce waste across cultivation and processing. The same data ANVISA demands for oversight can become the foundation for continuous improvement in operations and product quality.
The company argues that producers who build clean, structured compliance data from day one will have a significant operational advantage as the market scales. That is where it sees the biggest long-term opportunity in Brazil. It is not only offering a digital ledger of what happened but also an operations intelligence layer for a medical cannabis industry that is being built under the scrutiny of a pharmaceutical-grade regulator.
Operating in more than 24 countries has also given GrowerIQ a template for what may come next in other jurisdictions. Brazil fits a growing pattern in which regulators define the outcomes they want, such as full traceability, robust lab data, and verifiable facilities, and then allow operators to choose how to deliver them. For companies building technology for Brazil cannabis compliance and for similar emerging markets, local alliances like the one with Milgrows may become an effective way to influence how compliance norms take shape in new regulated cannabis economies.
Details in this story are based in part on a Q and A CannabisTech conducted with GrowerIQ. For more information, the full GrowerIQ news release on Brazil cannabis compliance and the Milgrows alliance can be found here.
